Hypertension

High blood pressure at a younger age could forecast cardiovascular problems in adulthood.

The US FDA has granted a second approval to treprostinil (Tyvaso) inhalation solution, this time for the treatment of patients pulmonary hypertension associated with interstitial lung disease (PH-ILD) to help improve exercise ability.

Results of the phase 2 PULSAR trial indicate sotatercept could be an effective adjunct to background medical therapy for reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

Researchers compare the NYHA class identifier with KCCQ-QS.

The analysis was less statistically powered when comparing sibling discordant.

A Michigan State University-led analysis suggests just 3% of patients at high risk for primary aldosteronism underwent screening for the hypertensive disorder.

A systematic review and meta-analysis of data from more than 280 studies is providing insight into the potential increase in risk of depression and other psychiatric adverse events associated with beta-blockers.

A recent study found that time-restricted diets did not induce changes in blood pressure or lipid profiles, but did lead to reductions in weight loss.

An analysis of data from more than 16k Hispanic/Latino individuals indicates the prevalence of cardiovascular risk factors among those with a history of stroke/TIA was greater than previously thought and many are unaware of these risk factors.

Obese individuals were found to have a higher odds ratio of developing IIH compared to non-obese people.

An analysis of data from the International Consortium of Blood Pressure-Genome Wide Association Studies suggests every 1 mmHg increase in blood pressure was linked to a 1.4-2.6% increase in risk of atrial fibrillation.

Low-density lipoprotein cholesterol level was lower by approximately 19 mg per deciliter and systolic blood pressure was lower by approximately 5.8 mm Hg with the polypill and with combination therapy than with placebo.

The University of Chicago hypertension expert discusses new ADA recommendations for cardiovascular risk management.

In this column, Dr. Paul Thompson offers his perspective on the use of digoxin and explains why he has maintained use in certain patient populations despite its waning popularity in recent years.

Results of the REPLACE COVID trial offer clinicians an opportunity to better understand the impact of discontinuing therapy with ACEs or ARBs.

Patients who continue RAS therapy had a lower risk of kidney replacement therapy.

A retrospective analysis of more than 7k patients from the ACCORD trial suggests intensive blood pressure and intensive blood glucose control could reduce the risk of cardiovascular autonomic neuropathy in diabetics.

Novartis indicates they will address manufacturing issues cited by the FDA.

An analysis of more than 7k patients from Brazil suggests high blood pressure at any age and for any amount of time was linked to accelerated cognitive decline later in life.

Data from more than 37k patients in the UK Biobank study suggests hypertension in midlife was linked to an increased risk of white matter hyperintensities later in life.

2020 was the year when regulators, clinicians, and patients had no choice but to embrace the concept of wearable monitoring devices. But it’s been a long time coming for the technology class.

About 20% of 81 positive patients experienced critical neurological complications; further, half had a pre-existing history of high blood pressure or type 2 diabetes.

The shortage of kidney donors begs a need to consider safe approaches to expand the donor pool.

In data presented at AAO, investigators examine the impact of anti-VEGF injections on ocular hypertension.

In data presented at AAO 2020, researchers discover new methods for detecting different underlying conditions.